{"id":3029,"date":"2012-09-30T18:13:25","date_gmt":"2012-09-30T18:13:25","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/research-and-markets-psoriasis-event-driven\/"},"modified":"2012-09-30T18:13:25","modified_gmt":"2012-09-30T18:13:25","slug":"research-and-markets-psoriasis-event-driven","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/research-and-markets-psoriasis-event-driven\/","title":{"rendered":"Research and Markets: Psoriasis (Event Driven)"},"content":{"rendered":"<p><p>      DUBLIN--(BUSINESS WIRE)--    <\/p>\n<p>      Research and Markets (<a href=\"http:\/\/www.researchandmarkets.com\/research\/sn7nsz\/psoriasis_event\" rel=\"nofollow\">http:\/\/www.researchandmarkets.com\/research\/sn7nsz\/psoriasis_event<\/a>)      has announced the addition of Decision Resources, Inc's new      report \"Psoriasis (Event Driven)\" to their offering.    <\/p>\n<p>      Despite the major impact psoriasis has on patients' quality      of life, physicians believe many patients are untreated or      undertreated, offering important commercial opportunities for      current and emerging agents targeting this indication. During      our ten-year forecast period, intense competition between the      TNF-a inhibitors etanercept and adalimumab and the      interleukin inhibitor ustekinumab has the potential to      transform current treatment algorithms and define new market      leaders. These current therapies will vie for share with      several emerging agents with novel mechanisms of action and      distinct risk-benefit profiles.    <\/p>\n<p>      Key Topics Covered:    <\/p>\n<p>      Executive Summary    <\/p>\n<p>      What are the key parameters of the psoriasis market?    <\/p>\n<p>      What factors are driving the market for psoriasis therapies?    <\/p>\n<p>      What factors are constraining the market for psoriasis      therapies?    <\/p>\n<p>      What are the drug development activities of note in      psoriasis?    <\/p>\n<p>      What do the experts say?    <\/p>\n<\/p>\n<p>See original here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/research-markets-psoriasis-event-driven-092200351.html;_ylt=A2KJjam6i2hQW1gA9Jv_wgt.\" title=\"Research and Markets: Psoriasis (Event Driven)\">Research and Markets: Psoriasis (Event Driven)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> DUBLIN--(BUSINESS WIRE)-- Research and Markets (<a href=\"http:\/\/www.researchandmarkets.com\/research\/sn7nsz\/psoriasis_event\" rel=\"nofollow\">http:\/\/www.researchandmarkets.com\/research\/sn7nsz\/psoriasis_event<\/a>) has announced the addition of Decision Resources, Inc's new report \"Psoriasis (Event Driven)\" to their offering. Despite the major impact psoriasis has on patients' quality of life, physicians believe many patients are untreated or undertreated, offering important commercial opportunities for current and emerging agents targeting this indication. During our ten-year forecast period, intense competition between the TNF-a inhibitors etanercept and adalimumab and the interleukin inhibitor ustekinumab has the potential to transform current treatment algorithms and define new market leaders.  <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/research-and-markets-psoriasis-event-driven\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-3029","post","type-post","status-publish","format-standard","hentry","category-psoriasis"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/3029"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=3029"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/3029\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=3029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=3029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=3029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}